English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 20 July 2022, 13:30 HKT/SGT
Share:
        

Source: UCrest Berhad / Malaysian Genomics Resource Centre Bhd
UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide

PETALING JAYA, Malaysia, July 20, 2022 - (ACN Newswire) - UCrest Berhad (ACE Market: 0005) and Malaysian Genomics Resources Centre Berhad, (ACE Market: 0155) announced today that they have signed a collaborative agreement to integrate genomic testing services into digital health platform, iMedic(TM), elevating healthcare services to the next level.

Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]

Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]

Under this agreement, a virtual genome service centre will be developed on iMedic platform enabling the genomic testing services of MGRC to be made available to the hospitals and clinics (B2B), widening its market access not just in Malaysia, but globally. Additionally, the genomic testing services will also be made available to patients directly (B2C). Patients' genomic data from their test results will be integrated into Electronic Medical Records (EMR) making it accessible by doctors and patients in the process of consultation and management, resulting in improved accuracy in diagnosis and treatment.

UCrest is the leading technology provider of digital health platform with offices in Malaysia, Singapore, China and Taiwan providing access to thousands of doctors, including many from the leading hospitals in the United States and China, to provide online consultation and management of patients anywhere in the globe.

Malaysian Genomics is a leading genomics and biopharmaceutical company in ASEAN for genome sequencing, bioinformatics analysis, and genetic screening, and various types of immunotherapy including CAR T-Cell therapy for the treatment of certain cancers.

The global genomics market size was valued at US$20.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.35% from 2021 to 2028. The Asia Pacific genome sequencing market will grow by 15.6% annually over 2022-2030 due to growing government funding initiatives in genomics projects related to cancer treatment and the utilization of genomics in personalized medicine targeting chronic disease prevention and management.

Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "We are looking forward to working with UCrest as its iMedic platform will provide us an opportunity to reach out to markets beyond Malaysia. The platform will also enable us to strengthen our B2B and B2C channels. This collaboration can play an important role in providing physicians with easy access to the latest in genetic screening, in support of enhancing their medical practice and improving patient outcomes."

"This partnership with Malaysian Genomics allows us to enhance our vision of integrating preventive and precision medicine into iMedic where genome data will empower the patients to better prevent and manage the chronic diseases with the online consultation of doctors," said Mr. Eg Kah Yee, Chief Executive Officer of UCrest. "Cancer, Cardiovascular Diseases (CVD), diabetic, asthma, sleep apnea and many other chronic diseases can be prevented, managed or treated more effectively with the addition of the genome services," he added.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
UCrest Berhad: 0005 [BURSA: UC] https://www.ucrest.net/

Topic: Press release summary
Source: UCrest Berhad / Malaysian Genomics Resource Centre Bhd

Sectors: Daily News, BioTech, Healthcare & Pharm, Digitalization, Local Biz
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
DENSO Establishes Strategic Partnership with Oracle to Modernize Core Supply Chain Systems  
Wednesday, April 15, 2026 10:25:00 AM
Fujitsu and Chugoku Electric Power T&D sign IP licensing agreement to accelerate renewable energy integration and advance power transmission maintenance   
Wednesday, April 15, 2026 10:07:00 AM
Doubleview Gold Corp. Announces Filing of Preliminary Economic Assessment Technical Report for the Hat Project  
Apr 15, 2026 00:29 HKT/SGT
Datavault AI and AgSensor Solutions Announce Consulting Partnership to Tokenize High-Value Agricultural Data Assets  
Apr 14, 2026 21:00 HKT/SGT
P&G and OMP Showcase the Path to Autonomous, Decision-Centric Planning at Gartner Supply Chain Symposium/Xpo 2026  
Apr 14, 2026 21:00 HKT/SGT
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives  
Apr 14, 2026 19:05 HKT/SGT
Global Sports Brand U.S. Polo Assn. Unveils Field X Fashion, Issue 3  
Apr 14, 2026 19:00 HKT/SGT
HKTDC launches GoGlobal Connect to help mainland firms go global via Hong Kong  
Apr 14, 2026 18:40 HKT/SGT
Seres Cements Luxury EV Leadership with Record Sales and RMB12.51 Billion R&D Investment  
Apr 14, 2026 09:29 HKT/SGT
Datavault AI Announces Upcoming Listing of Meme Coin Portfolio and Institutional RWA Token Suite on the Biconomy Exchange  
Apr 13, 2026 23:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575